Core Viewpoint - MSCI announced its quarterly index adjustments for May 2025, adding 30 stocks to its global standard index, including five A-shares: Chipone Technology, Baillie Gifford, Huatai Medical, Light Media, and Haizhi Science [1][4][7]. Group 1: MSCI Index Adjustments - MSCI's May adjustments included the addition of 30 stocks and the removal of 61 stocks from its global standard index [6]. - The largest new additions to the MSCI global standard index by market capitalization include Ryanair Holdings, Sigma Healthcare, and International Airlines Group [6]. - The MSCI Emerging Markets Index added three major stocks: ADNOC Gas, Dubai Electricity & Water Authority, and Baillie Gifford [6]. Group 2: A-Share Specifics - In the MSCI China A-share index, five stocks were added: Chipone Technology, Baillie Gifford, Huatai Medical, Light Media, and Haizhi Science, while 15 stocks were removed, including Hisense Home Appliances and FAW Jiefang [7][9]. - Additionally, one Hong Kong stock, Chongqing Rural Commercial Bank, was added, while Shanghai Pharmaceuticals and COSCO Shipping Energy were removed [8]. Group 3: Market Reactions - The U.S. stock market showed mixed results, with the Dow Jones down 0.64%, the S&P 500 up 0.72%, and the Nasdaq up 1.61%, driven by strong performance in chip stocks [2][12]. - Nvidia's stock surged by 5.63%, contributing significantly to the Nasdaq's rise, while AMD also saw a 4.01% increase [2][14]. - AMD announced a strategic partnership with Humain worth $10 billion to advance global artificial intelligence, indicating strong growth potential in the semiconductor sector [15].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The report emphasizes the focus on innovative drugs and the recovery of consumer demand as key drivers for investment in the pharmaceutical sector [3] - The TCE (T-cell Engager) solid tumor pipeline is highlighted, with Janux and Vir making significant progress in their development plans [5][13] - The pharmaceutical sector saw a 1.01% increase in the second week of May, underperforming the CSI 300 index by 1 percentage point, ranking 26th among 31 sub-industries [6][15] Summary by Sections TCE Solid Tumor Pipeline Update - Janux announced that JANX007 (PSMA/CD3) will enter the 1b expansion trial, targeting taxane-naive patients, marking a significant step for TCE in solid tumors [5][13] - Vir has registered VIR-5525 (EGFR/CD3) for a first-in-human trial, expected to start this month, focusing on EGFR-expressing NSCLC [5][13] Market Performance - In the second week of May, the pharmaceutical sector increased by 1.01%, with the medical device sector showing the highest growth at 1.98% [6][19] - The report notes that the offline pharmacy sector experienced the largest decline, dropping by 1.65% [19] Recommended and Benefiting Stocks - Recommended stocks in the pharmaceutical and biotechnology sector include: - Innovative drugs: Zai Lab, Innovent Biologics, and others [7] - Traditional Chinese medicine: Dong-E E-Jiao, Jiangzhong Pharmaceutical, and others [7] - Medical devices: Mindray Medical, and others [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The report emphasizes the focus on innovative drugs and the recovery of consumer demand as key drivers for investment in the pharmaceutical sector [3] - The TCE (T-cell Engager) solid tumor pipeline is highlighted, with Janux and Vir making significant progress in their development plans [5][13] - The pharmaceutical sector saw a 1.01% increase in the second week of May, underperforming the CSI 300 index by 1 percentage point, ranking 26th among 31 sub-industries [6][15] Summary by Sections TCE Solid Tumor Pipeline Update - Janux announced that JANX007 (PSMA/CD3) will enter the 1b expansion trial, targeting taxane-naive patients, marking a significant step for TCE in frontline indications [5][13] - Vir has registered VIR-5525 (EGFR/CD3) for a first-in-human trial, expected to start this month, focusing on EGFR-expressing NSCLC [5][13] Market Performance - In the second week of May, the pharmaceutical sector increased by 1.01%, with the medical device sector showing the highest growth at 1.98% [6][19] - The report notes that the offline pharmacy sector experienced the largest decline, dropping by 1.65% [19] Recommended and Benefiting Stocks - Recommended stocks in the pharmaceutical and biotechnology sector include: - Innovative drugs: Zai Lab, Innovent Biologics, Kelun-Biotech, Yifan Pharmaceutical, and others [7] - Traditional Chinese medicine: Dong-E E-Jiao, Jiangzhong Pharmaceutical, and others [7] - Medical devices: Mindray, Aohua Endoscopy, and others [7]

核心观点 4 月29 日，公司发布2024 年年度业绩报告，实现营业收入223.58亿元，同比-0.36%，实现归母净利润 5.19 亿元，同比下降44.13%，实现扣非归母净利润4.96 亿元，同比下降41.18%，实现基本每股收益0.68 元，业绩低于我们预期。展望2025 年，公司门店结构持续优化，火炬项目稳步落地，零售板块毛利率 有望持续改善，叠加公司持续落地降本增效举措，我们期待公司利润增速加速恢复。 事件 公司发布2024 年年度业绩报告，业绩低于我们预期4 月29 日，公司发布2024 年年报及2025 年一季报， 2024年实现营业收入、归母净利润及扣非归母净利润分别为223.58 亿元、5.19亿元及4.96亿元，分别同 比下降0.36%、44.13%及41.18%。 2024 年，公司营业收入同比下降0.36%，主要由于：1）公司24 年优化部分盈利能力较差的门店，零售 板块收入同比下降1.25%；2）行业竞争压力加剧，部分老店增长放缓，但公司加盟、联盟及分销业务 增长5.92%为31.05 亿元，较为稳健。归母净利润同比下降44.13%，扣非归母净利润同比下降41.18%， 慢于收入增长 ...

健之佳（605266）公告，2025年第一季度营业收入22.94亿元，同比下降0.85%。归属于上市公司股东的 净利润3352.56万元，同比下降35.85%。基本每股收益0.22元/股，同比下降35.29%。 ...